Alnylam Pharmaceuticals Stock Filter Stocks by Fundamentals
ALNY Stock | USD 154.39 2.42 1.59% |
Alnylam Pharmaceuticals fundamentals help investors to digest information that contributes to Alnylam Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alnylam Stock. The fundamental analysis module provides a way to measure Alnylam Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alnylam Pharmaceuticals stock.
Alnylam | Price to Earning |
Alnylam Price to Earning Analysis
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 494.1M | 585.7M | 713.0M | 748.7M | Total Assets | 3.6B | 3.5B | 3.8B | 4.0B |
Alnylam Price to Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for Alnylam Pharmaceuticals is extremely important. It helps to project a fair market value of Alnylam Stock properly, considering its historical fundamentals such as Price to Earning. Since Alnylam Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alnylam Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alnylam Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Competition |
Alnylam Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, the price to earning indicator of Alnylam Pharmaceuticals is roughly 0.0null. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Price to Earning (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
All Next | Launch Module |
Alnylam Fundamentals
Return On Equity | -15.01 | ||||
Return On Asset | -0.0478 | ||||
Profit Margin | (0.24) % | ||||
Operating Margin | (0.26) % | ||||
Current Valuation | 18 B | ||||
Shares Outstanding | 125.95 M | ||||
Shares Owned By Insiders | 0.39 % | ||||
Shares Owned By Institutions | 95.08 % | ||||
Number Of Shares Shorted | 2.69 M | ||||
Price To Earning | (22.92) X | ||||
Price To Book | 142.92 X | ||||
Price To Sales | 10.44 X | ||||
Revenue | 1.83 B | ||||
Gross Profit | 868.6 M | ||||
EBITDA | (228.12 M) | ||||
Net Income | (440.24 M) | ||||
Cash And Equivalents | 2.27 B | ||||
Cash Per Share | 18.41 X | ||||
Total Debt | 2.68 B | ||||
Debt To Equity | 5.63 % | ||||
Current Ratio | 3.48 X | ||||
Book Value Per Share | (1.75) X | ||||
Cash Flow From Operations | 104.16 M | ||||
Short Ratio | 2.30 X | ||||
Earnings Per Share | (3.53) X | ||||
Price To Earnings To Growth | (0.49) X | ||||
Target Price | 222.59 | ||||
Number Of Employees | 2.1 K | ||||
Beta | 0.39 | ||||
Market Capitalization | 19.08 B | ||||
Total Asset | 3.83 B | ||||
Retained Earnings | (7.01 B) | ||||
Working Capital | 2.01 B | ||||
Current Asset | 1.11 B | ||||
Current Liabilities | 62.1 M | ||||
Z Score | 2.62 | ||||
Net Asset | 3.83 B |
About Alnylam Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1665 people.
Pair Trading with Alnylam Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Alnylam Stock
0.83 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Alnylam Stock
0.93 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
0.92 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
0.86 | MGNX | MacroGenics Financial Report 14th of May 2024 | PairCorr |
0.79 | MDWD | Mediwound Financial Report 4th of June 2024 | PairCorr |
0.72 | TCRX | Tscan Therapeutics Financial Report 8th of May 2024 | PairCorr |
The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alnylam Pharmaceuticals Piotroski F Score and Alnylam Pharmaceuticals Altman Z Score analysis. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.53) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.